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Abstract
Viruses are obligate intracellular parasites and therefore their replication completely depends on host cell factors. In case of
the hepatitis C virus (HCV), a positive-strand RNA virus that in the majority of infections establishes persistence, cyclophilins
are considered to play an important role in RNA replication. Subsequent to the observation that cyclosporines, known to
sequester cyclophilins by direct binding, profoundly block HCV replication in cultured human hepatoma cells, conflicting
results were obtained as to the particular cyclophilin (Cyp) required for viral RNA replication and the underlying possible
mode of action. By using a set of cell lines with stable knock-down of CypA or CypB, we demonstrate in the present work
that replication of subgenomic HCV replicons of different genotypes is reduced by CypA depletion up to 1,000-fold whereas
knock-down of CypB had no effect. Inhibition of replication was rescued by over-expression of wild type CypA, but not by a
mutant lacking isomerase activity. Replication of JFH1-derived full length genomes was even more sensitive to CypA
depletion as compared to subgenomic replicons and virus production was completely blocked. These results argue that
CypA may target an additional viral factor outside of the minimal replicase contributing to RNA amplification and assembly,
presumably nonstructural protein 2. By selecting for resistance against the cyclosporine analogue DEBIO-025 that targets
CypA in a dose-dependent manner, we identified two mutations (V2440A and V2440L) close to the cleavage site between
nonstructural protein 5A and the RNA-dependent RNA polymerase in nonstructural protein 5B that slow down cleavage
kinetics at this site and reduce CypA dependence of viral replication. Further amino acid substitutions at the same cleavage
site accelerating processing increase CypA dependence. Our results thus identify an unexpected correlation between HCV
polyprotein processing and CypA dependence of HCV replication.
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Introduction
The hepatitis C virus (HCV) is a hepatotropic virus that has a
high propensity to establish persistence. At present, more than 170
million people suffer from chronic hepatitis C [1]. Current therapy
of this disease is based on the combination of pegylated interferon-
alpha and ribavirin. However, sustained viral response rates are
not satisfying and side-effects associated with this therapy are high.
Thus, the development of alternative and more effective strategies
to counteract HCV infection are of great importance. One
promising drug showing potent anti HCV function is cyclosporine
A (CsA). The cyclic undecapeptide CsA is a secondary metabolite
of the fungus Tolypocladium inflatum and was originally discovered as
powerful immunosuppressive drug [2]. The immunosuppressive
properties of CsA are due to its ability to block the phosphatase
Calcineurin in activated T cells [3] by binding with high affinity to
cyclophilins (CyPs) [4]. Because of the non-immunosuppressive
properties combined with profound antiviral activity, CsA
derivatives such as DEBIO-025 [5], NIM811 [6], and SCY-635
are more likely to be used as anti HCV agents. Unlike CsA, these
molecules binds to CyPs but do not display calcineurin inhibition.
As a member of the Flaviviridae family, HCV has a positive
strand RNA genome encoding a single polyprotein that is cleaved
by cellular and viral proteases into 10 different proteins (reviewed
in [7,8]). The structural proteins core, envelope protein 1 (E1) and
E2 reside in the N-terminal region of the polyprotein and they are
the major constituents of the virus particle. Virus assembly and
release requires p7, a presumed viroporin [9–11] and nonstruc-
tural protein 2 (NS2) that contains a complex N-terminal trans-
membrane domain and a C-terminal protease domain responsible
for cleavage between NS2 and NS3 [12,13]. The latter is
composed of two domains, an N-terminal protease domain which
is activated via the NS4A cofactor and a C-terminal helicase
domain. NS4B most likely plays a major role in the induction of
membrane alterations that are required for the assembly of viral
replication complexes. NS5A is an RNA binding protein required
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dependent RNA polymerase (RdRp). Cleavage of the polyprotein
in the NS3 to NS5B region is mediated by the NS3/4A protease
complex. Processing at the NS3-4A site is a rapid intramolecular
reaction. Subsequent cleavages take place intermolecularly in the
following preferred, but not obligatory order: NS5A-B, NS4A-B,
NS4B-5A [17,18]. Replication of HCV occurs in the cytoplasm of
infected cells in distinct virus-induced compartments designated
the membranous web [19]. It is a complex membrane network
composed of an accumulation of membranous vesicles of various
sizes and interspersed lipid droplets which are the presumed sites
of HCV assembly [16,20–22]. It is thought that core and NS5A
are key players in mediating transfer of viral proteins and RNA
from viral replication complexes to lipid droplets to trigger
assembly [16,21,22].
Our knowledge about cellular proteins required for HCV RNA
replication and virus assembly is scarce, but recent studies suggest
that cyclophilins (Cyp) play an important role. Cyps are molecular
chaperones catalyzing the cis-trans isomerization of proline
residues and hence are called peptidyl-prolyl cis-trans-isomerases
(PPIases). Up to now 16 Cyp members have been identified with 7
major members found in humans (CypA-E, Cyp40, CypNK; [23]).
Cyps share a common domain, but other than their PPIase activity
differ in subcellular distribution and function. Conflicting data
exist as to which Cyp is required for HCV replication. Watashi
and coworkers reported that CypB is important for viral
replication and they observed a direct binding of CypB to NS5B
which results in enhanced RNA binding and thus increased RNA
polymerase activity [24]. Others reported that CypA or CypA, B
and C are required for HCV replication [25,26]. For both CypA
[26] and CypB [24,27,28] direct interactions with NS5B were
reported arguing for a direct involvement of cyclophilins in HCV
RNA replication. However, the underlying mechanism is not
known.
We report here that an enzymatically active CypA is essential
for HCV replication and describe an interrelation between CypA
requirement for HCV replication and processing kinetics at the
NS5A-B site.
Results
CypA but not CypB is essential for HCV replication and
virus production
Contrary opinions about which type of Cyp is essential for HCV
prevail in current literature [24,26]. To clarify these contradictions
we established a panel of cell lines derived from the highly
permissive Huh-7 subclones Huh7.5 and Huh7-Lunet by
retroviral transduction of shRNAs targeting the 39 non-coding
region of CypA or CypB (Fig. 1). Cell pools transduced with the
retroviral vector expressing an unrelated shRNA were generated
as a control. Transduced shRNAs lead to a profound and stable
reduction of the expression of CypA or CypB in the respective cell
pools as detected by Western blot (Fig. 1A) and immunofluores-
cence analysis (Fig. 1B–C).
To determine the impact of reduced CypA or CypB expression
on HCV RNA replication, cells were transfected with a
subgenomic JFH1 luciferase reporter replicon RNA (sgNS3/
JFH1-Luc; Fig. 2A, upper panel). Cells were lysed 4, 24, 48 and
72 h after transfection and replication was scored by measuring
luciferase activity in cell lysates. Luciferase activity was normalized
to the 4 h value, reflecting transfection efficiency. Replication was
not affected by CypB knock-down and was comparable between
naı ¨ve and vector control-transduced Huh7-Lunet or Huh7.5 cells
(Fig. 2A, left and right panel, respectively). However, when we
transfected the same replicon into cells with the stable CypA
knock-down luciferase activity was reduced more than 100-fold at
the early time point (24 h post transfection) in case of Huh7-Lunet
cells and about 50-fold in case of Huh7.5 cells. Only at the latest
time point (72 h post transfection) luciferase activities were
comparable in all transfected cell lines. This kinetic is due to the
fact that replication of JFH1 is limited by the host cell [29]. For
this reason RNA replication phenotypes are often only detectable
at early time points after transfection before host cell factor(s)
(other than CypA) become limiting and thus restrict HCV
replication in naı ¨ve cells. Therefore, HCV replication in cells
with the CypA knock-down can ‘catch up’ until it reaches wild
type level [30]. By using the luciferase values (which because of the
very short half life of luciferase are ideally suited to determine
replication kinetics) we calculated the apparent doubling time of
HCV RNA during the exponential phase in the various cell lines.
We found that apparent doubling time in naı ¨ve and control cells
were in the range of 3.7 h whereas apparent doubling time was
11.4 h in Huh7-Lunet cells with stable CypA knock-down. In case
of Huh7.5-derived cell lines apparent doubling times were 3.6 h
and 7.4 h for control and CypA knock-down cells, respectively.
Thus results obtained with both cell lines were remarkably similar
arguing against a cell line-specific phenotype.
Given the controversial discussion on genotypic differences with
respect to Cyp-dependence of HCV replication, we also determined
the impact of CypA and CypB knock-down on replicons derived
from the genotype 1b isolate Con1. As shown in Fig. 2B, replication
of a highly adapted Con1-derived replicon (Con/ET; [31]) was
completely blocked in Lunet cells with CypA knock-down as
deduced from the comparable drop of luciferase expression in cells
transfected with this replicon or the replication defective NS5B
activesitemutant(Con/GND).Incontrast,replication ofCon1/ET
was completely unaffected by knock-down of CypB expression. In
case of Huh7.5 derived cell lines that support Con1 RNA
replication to a much lower extent, we also observed a complete
inhibition of replication in CypA knock-down cells, but in some
experiments a slight inhibition in cells with a CypB knock-down was
found as well (Fig. 2B, right panel). The latter was however, at the
limit of statistical significance (Mann-Whitney-Test).
Author Summary
Owing to limited genetic information, viruses have to
exploit host cells to achieve efficient production of virus
progeny. Host cell factors and pathways therefore play an
important role for virus replication and thus represent a
possible target for antiviral therapy. In case of the hepatitis
C virus (HCV), an RNA virus infecting liver cells and causing
chronic liver disease, host cell cyclophilins were shown to
play an important role in replication. Pharmacological
inhibition of cyclophilins, which are catalysts of protein
folding, causes profound inhibition of HCV replication, but
neither the underlying mechanism by which cyclophilins
contribute to viral replication, nor the exact nature of the
cyclophilin are known. In this study we demonstrate that
HCV replication and presumably also virus particle
assembly requires cyclophilin A (CypA), which can be
blocked by the cyclosporine analogue DEBIO-025. We
identify mutations affecting proteolytic cleavage of the
viral polyprotein that render HCV replication less depen-
dent on CypA and thus cause DEBIO-025 resistance.
Studies with additional mutants reveal a correlation
between polyprotein cleavage kinetics and CypA depen-
dence. Our results support a model by which CypA
activates the viral replicase in a manner that depends on
the kinetics with which the viral polyprotein is cleaved.
Role of Cyclophilin A for HCV Replication
PLoS Pathogens | www.plospathogens.org 2 August 2009 | Volume 5 | Issue 8 | e1000546Figure 1. Major role of CypA for HCV replication. (A–C) Stable knock-down of CypA (left panel) or CypB (right panel) in Huh7.5 and Huh7-Lunet
cells was achieved by retroviral transduction of shRNAs targeting the 39 NTR of either mRNA. As a reference, cells were transduced with the retroviral
vector encoding an unrelated shRNA sequence (sh-control). (A) Knock-down efficiency was determined by western blot with a CypA or a CypB
specific antibody. Beta-actin was used as loading control. (B, C) Detection of CypA (B) and CypB (C) knock-down in Huh7-Lunet and Huh7.5 cells via
indirect immunofluorescence analysis. Cells were seeded onto glass cover slips and fixed with methanol 72 h later. Immunostaining was performed
with CypA or CypB specific antibodies.
doi:10.1371/journal.ppat.1000546.g001
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PLoS Pathogens | www.plospathogens.org 3 August 2009 | Volume 5 | Issue 8 | e1000546Figure 2. Impact of stable CypA or CypB knock-down on RNA replication of genotype 2a and 1b replicons. (A) Huh7-Lunet cells (left
panel) and Huh7.5 cells (right panel) either stably transduced with the unrelated shRNA control (sh-control) or a vector encoding the CypA- or CypB-
specific shRNA or naive cells were transfected with a subgenomic luciferase reporter replicon derived from the HCV isolate JFH1 (sgNS3/JFH1-Luc,
shown at the top). Cells were lysed at given time points after transfection, and luciferase activity (expressed in relative light units, RLU) in cell lysates
was determined. Values are normalized to the 4 h value that reflects transfection efficiency and that was set to 100%. Means and standard deviations
of a representative experiment are shown. Luc, firefly luciferase; sg, subgenomic replicon. (B) Impact of CypA or CypB knock-down on replication of
Con1. Schematic diagrams of the two Con1-derived constructs are shown in the top. They are composed of the HCV 59 NTR, the IRES of poliovirus for
high-level expression of the firefly luciferase gene, the EMCV IRES, the HCV replicase coding region and the 39 NTR. To enhance RNA replication, 3 cell
culture adaptive mutations (labelled with asterisks) have been introduced in case of the wild type (ET) replicon [31]. The GND mutant contains an
active site mutation destroying NS5B RdRp activity, thus serving as control to measure decay kinetics of luciferase activity expressed from transfected
input RNA. Huh7-Lunet cells (left panel) and Huh7.5 cells (right panel) specified below the schematics of the replicons were transfected and
replication was analyzed as described in the legend of panel A. One experiment of two independent repetitions, each performed in duplicate is
shown.
doi:10.1371/journal.ppat.1000546.g002
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replication is specific for this virus or applies to other flaviviruses
by analyzing replication of a Dengue virus 2 (New Guinea C
isolate) replicon in the same cell lines. We found that RNA
replication of Dengue virus was not affected by CypA or CypB
knock-down in Huh7-Lunet cells (Fig. S1, left panel) whereas in
Huh7.5 cells with a CypA knock-down a slight reduction of
replication was found (right panel). However, also in this case this
difference was at the limit of statistical significance. In summary,
we concluded that CypA is an essential host cell factor required for
RNA replication of HCV but not Dengue virus, whereas CypB
appears to play no role for HCV replication.
To study the impact of these knock-downs on replication of full
length HCV genomes we used a bicistronic reporter genome (Jc1-
Luc; Fig. 3A, upper panel). It is derived from the highly assembly
competent chimera Jc1 composed of the genotype 2a isolate J6 and
JFH1 that are fused at a distinct site in the N-terminal trans-
membrane domain of NS2 [32] (Fig. 3A). For this and all
subsequent studies phenotypic analyses were performed primarily
in Huh7-Lunet cells because of the more potent knock-down of
CypA and CypB expression as compared to Huh7.5-derived cell
lines (Fig. 1). A very potent inhibition of Jc1-Luc replication was
found in CypA, but not CypB knock-down cells (Fig. 3A, lower left
panel). In fact, the inhibition was much stronger compared to the
one observed with the subgenome and replication did not recover
evenatlatertimepoints.Infectivitywasnotdetected insupernatants
ofCypAknock-downcells(Fig.3A,rightpanel),butnotsignificantly
reduced in supernatants of CypB knock-down cells.
The profound inhibition of Jc1-Luc replication in CypA knock-
down cells might be due to the less robust replication of this
Figure 3. Increased inhibition of RNA replication of JFH1 full length genomes and NS2-containing replicons by CypA knock-down.
(A) Huh7-Lunet cells stably transduced with the control vector (sh-control) or the vector encoding the CypA- or CypB-specific shRNA were transfected
with the Jc1-Luc genome (shown at the top). Replication of the genome was determined by luciferase assay with cell lysates prepared at given time
points (left panel). Infectivity released from transfected cells was measured by inoculation of naive Huh7.5 cells with culture supernatants harvested
at given time points after transfection and luciferase activity was determined in infected cells 72 h after inoculation (right panel). Means and standard
deviations of two independent experiments are shown. The dark shaded region in the HCV genome map in the top indicates the J6-derived
sequence; the white region corresponds to JFH1. (B) Huh7-Lunet cells were transfected with the Jc1 genome and accumulation of intracellular core
protein amounts was determined by core-specific ELISA (upper panel). Kinetic of core release is shown in the middle panel. Core protein in culture
supernatants of transfected cells was normalized to total core protein amounts (intra- plus extracellular core). Kinetic of release of infectious virus
particles is shown in the bottom panel. Infectivity was determined by TCID50 assay. Background of the assay is indicated by the horizontal dashed
line. (C) Huh7-Lunet cells were transfected with JFH1-derived subgenomic replicons encoding an NS3 to 5B or NS2 to 5B replicase of JFH1 (sgNS3/
JFH1-Luc and sgNS2/JFH1-Luc, respectively) and replication was determined by luciferase assay as described in the legend to panel (A). Background
of the assay was determined with the sgNS3-derived replicon with an active site mutation destroying NS5B RdRp activity (DGDD). A representative
experiment of three independent repetitions, each performed in duplicate is shown.
doi:10.1371/journal.ppat.1000546.g003
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[33]. Alternatively, CypA dependence of JFH1 full length HCV
genomes and subgenomes may differ. We addressed these
possibilities by transfection of CypA knock-down cells with a full
length genome lacking heterologous sequences. Owing to highest
assembly efficiency we used the Jc1 chimera (Fig. 3B). Viral
replication was scored by determination of intracellular core
protein amounts whereas virus production was determined by
measurement of core released into the supernatant of transfected
cells as well as infectivity titers in culture supernatant (TCID50; see
materials and methods). Replication of the Jc1 genome was
potently reduced in CypA knock-down cells, but unaffected by
CypB knock-down. In addition to impaired replication, core
release was also reduced as deduced from the relative core protein
amounts in cell lysate and culture supernatant. In agreement with
this profound block of replication and impaired assembly no
infectivity was detected in supernatants of CypA knock-down cells
even though virus titers in control cells were in the range of 10
5
TCID50/ml and higher.
The congruent results obtained with the genomic reporter
replicon and the Jc1 genome suggest that CypA targets an
additional viral factor outside of the minimal replicase (NS3 to
NS5B). We assumed that NS2 would be the most likely candidate
for three reasons. First, cleavage at the NS2-3 site by NS2 is
essential for RNA replication [34]; second, the structural proteins
core, E1 and E2 as well as p7 are dispensable for RNA replication
[35]; third, NS2 is required for HCV assembly [12,13]. To put this
assumption to the test we performed comparative transient
replication assays by using subgenomic JFH1 replicons encoding
either an NS2 to NS5B or NS3 to NS5B replicase (sgNS2/JFH1-
Luc and sgNS3/JFH1-Luc, respectively) (Fig. 3C). Replication of
the sgNS2 replicon was almost completely blocked in Huh7-Lunet
cells with a CypA knock-down and only slightly above background
as determined with the replication defective NS5B active site
mutant JFH1/DGDD. In contrast, replication kinetic of the sgNS2
RNA was well comparable between Huh7-Lunet cells with a
CypB knock-down and control cells that had been transduced with
a non-targeting luciferase shRNA. We note a lower replication of
the sgNS2 replicon in CypB knock-down cells at 24 h post
transfection as compared to the sgNS3 replicon, but this reduction
was also observed with control cells (Fig. 3C). At later time points,
replication of sgNS2 and sgNS3 replicons was comparable. In
summary these results provide genetic evidence that CypA also
targets a factor outside of the replicase, most likely NS2.
Isomerase activity of CypA is essential for HCV RNA
replication
Although the results described so far clearly support an
important role of CypA for HCV replication, we could not
exclude that the observed phenotype was due, at least in part, to
off-target effects. For this reason, we transduced the Huh7-Lunet
CypA knock-down cell lines with a CypA expression construct that
was not targeted by the shRNA (‘rescue’ cell line in Fig. 4). In
addition, we generated CypA knock-down cell lines expressing a
CypA mutant (H126Q) that retains less than 1% of wild type
isomerase activity [36,37]. As shown in Fig. 4A and B, CypA
expression levels achieved upon transduction of the shRNA-
resistant CypA genes was very high (Fig. 4A). In fact, by using
quantitative immunofluorescence we found that expression level of
CypA in wild type ‘rescue’ cell lines was about two-fold higher as
compared to sh-control cells (234+/24.7 counts per cell based on
8-bit gray value histograms, generated with the ImageJ software
package, versus 125+/225.3 counts per cell, respectively) see
materials and methods). Knock-down of CypA had no effect on
expression levels of CypB (Fig. 4B, lane 7) and vice versa (data not
shown). Upon transfection of CypA wt ‘rescue’ cells with sgNS3/
JFH1-Luc, RNA replication was fully restored (Fig. 4C) thus
excluding off-target effects of the shRNA that was used for
silencing of CypA expression. However, no rescue was obtained in
cells stably transduced with the H126Q mutant (Fig. 4C), arguing
that isomerase activity of CypA is essential for HCV RNA
replication.
CypA is the target for antiviral activity of the cyclosporine
analogue DEBIO-025
To gain further insight into the role of CypA for replication of
HCV, we wanted to take advantage of the fact that cyclosporine
(CsA) binds to and sequesters CypA [4] and causes a profound
inhibition of HCV replication [25,38]. Moreover, we have
recently shown that the cyclosporine analogue DEBIO-025 also
inhibits replication of HCV, but the cellular target of this
compound was not clear [5]. To clarify this question we first
compared the antiviral activity of CsA and DEBIO-025 side-by-
side in a JFH1 replicon system. Cells transfected with the sgNS3/
JFH1-Luc replicon that expresses the firefly luciferase (Fig. 2A,
upper panel) were treated 4 h post transfection for 72 h with
various concentrations of CsA or DEBIO-025. Cells were then
lysed and luciferase activity was determined. The JFH1 sub-
genome was potently inhibited both by CsA and DEBIO-025,
with the latter having a higher antiviral activity (about 3–4 fold
lower IC50 and IC90 (Fig. 5A)).
We next determined whether CypA is targeted by DEBIO-025
using transient replication assays with the same subgenomic JFH1
RNA. Transfected cells were treated with various concentrations
of DEBIO-025 and after 72 h luciferase activity contained in cell
lysates was determined. The results depicted in Fig. 5B show that
HCV replication was much more sensitive to DEBIO-025
treatment in CypA knock-down cells whereas IC50 and IC90
values determined in CypB knock-down cells were comparable to
naı ¨ve and control shRNA-transduced cells. Moreover, when dose-
response assays were performed with CypA wild type ‘rescue’ cell
lines, DEBIO-025 sensitivity was reduced even to beyond the level
determined for naı ¨ve cells (Fig. 5C). This enhanced resistance is
probably due to the elevated expression levels of CypA in the
rescue cell line as compared to naı ¨ve cells. Most importantly,
DEBIO-025 sensitivity was not affected by transduction of the
gene containing the CypA isomerase mutation (H126Q) suggest-
ing that an enzymatically active CypA is required for HCV RNA
replication or that this CypA protein binds DEBIO-025 with lower
efficiency. In summary, our results show that CypA is the target for
the antiviral activity of DEBIO-025 and that isomerase activity of
CypA appears to be required for HCV replication.
A mutation in the C-terminus of NS5A confers DEBIO-025
resistance and reduces dependence of HCV RNA
replication on CypA
Given the finding that DEBIO-025 can be used as a convenient
tool for the pharmacological inhibition of CypA and to study its role
in HCV RNA replication, we sought to identify the target of CypA
in the HCV replicase by selection for DEBIO-025 resistance. Due
to the high potency of DEBIO-025 and the small window between
IC50 and IC90 (0.2 mg/ml and 0.5 mg/ml; Fig. 5A), attempts to
select for resistance by using virus passage or cells persistently
infected with Jc1were not successful. Concentrations in the range of
the IC90 or above lead to rapid elimination of HCV from cell
cultures and treatment with a dose corresponding to the IC50 did
not sufficiently affect replication. We therefore utilized a selectable
Role of Cyclophilin A for HCV Replication
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the red fluorescent protein (RFP) in domain 3 of NS5A [39], which
allowed visualization of replicating HCV via RFP autofluorescence
in live cells. Huh7-Lunet cells were transfected with this sgNS3/
JFH1-neo/RFP replicon and cultured in double-selection medium
containing 500 mg/ml of G418 and 0 or 0.5 or 1 mg/ml of DEBIO-
025. After 18 cell passages, we had selected for a DEBIO-025
resistant cell pool with a calculated IC50 of about 1 mg/ml
corresponding to an about 5-fold lower sensitivity as compared to
non-selected cells (see Fig. 5A).
To identify mutations that confer increased DEBIO-025
resistance and thus presumably reduced CypA dependence,
replicons present in two independent RNA preparations of the
cell pool were prepared from DEBIO-025 selected cells. From
each RNA preparation the complete HCV coding region was
amplified in two overlapping fragments (Fig. 6A) and 3 or 4
molecular clones of each fragment were subjected to nucleotide
sequence analysis, respectively. As summarized in Table 1 and
Fig. 6A, 4 mutations were identified residing in the NS3 helicase
domain (Y1421F) or at various positions in NS5A. Two of these
were mapped to domain 2 of NS5A (D2229G, L2266F) and one to
the very C-terminus of domain 3 (V2440A). Quite surprisingly, we
have recently identified position 2440, which is close to the NS5A-
B cleavage site, as a major determinant of HCV assembly [40].
However, in case of this virus titer enhancing mutation (TEM) the
substituting amino acid residue was leucine instead of the alanine
found in the DEBIO-025 resistance selection.
Multiple sequence alignments covering HCV isolates of all
genotypes as deposited in the European HCV database
(euHCVdb) [41] revealed that all positions identified in DEBIO-
025 selected replicons are polymorphic (Table 1). The mutations
residing in the NS3 helicase and at the C-terminus of domain 3 of
NS5A appear to be natural variants, because the substituting
residues (phenylalanine in case of the helicase and alanine in case
of NS5A) are present in patient isolates (Table 1). Other
substituting residues are naturally found in case of the two
mutations in domain 2 of NS5A.
The impact of these 4 selected mutations on DEBIO-025
sensitivity was determined by transferring each mutation individ-
Figure 4. Rescue of HCV replication by overexpression of CypA
wt but not CypA H126Q in stable knock-down cells. (A) Huh7-
Lunet cells with a stable knock-down of CypA (lower left) were stably
transduced with a CypA wild type (wt) expression construct (CypA wt-
rescue; upper right) or a CypA expression construct carrying the H126Q
mutation (CypA H126Q-rescue; lower right) that are both resistant to
the shRNA. For comparison, Huh7-Lunet cells stably transduced with
the same expression vector containing the non-related control shRNA
(sh-control) are shown (upper left). Cells were analyzed by immunoflu-
orescence using a CypA-specific antibody. Note that CypA expression
levels are higher in the ‘rescue cells’ as compared to the vector control
cells (sh-control). (B) Lysates from cells specified in the top were
analyzed by Western blot using a CypA-specific antibody. Lane 6 shows
a Western blot of a lysate of Huh7-Lunet cells with a stable knock-down
of CypA and transduced with an empty vector (cell line sh-CypA vector
control-rescue). Beta-actin was used as a loading control. K-d, knock-
down; rescue, stable CypA knock-down cells transduced with CypA wt
or the H126Q mutant or empty expression vector, respectively. Loaded
samples are specified above each lane. (C) Restoration of HCV
replication by ectopic expression of CypA wt, but not CypA H126Q in
stable CypA knock-down cells. Huh7-Lunet cells specified in the top
were transfected with a bicistronic JFH1 reporter replicon (sgNS3/JFH1-
Luc) and RNA replication was determined by luciferase assay 24, 48 and
72 h post transfection. Values are normalized for transfection efficiency
by using the 4 h value. Means and standard deviations of a
representative experiment of two independent repetitions are shown.
doi:10.1371/journal.ppat.1000546.g004
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PLoS Pathogens | www.plospathogens.org 7 August 2009 | Volume 5 | Issue 8 | e1000546Figure 5. CypA is the target of the cyclosporine analogue DEBIO-025. (A) Dose-response curve for cyclosporine A (CsA) and DEBIO-025.
Huh7-Lunet cells transfected with JFH1 reporter replicon (sgNS3/JFH1-Luc, shown in the top of Fig. 2A) were incubated 4 h post electroporation with
escalating concentrations of CsA or DEBIO-025 and 72 h later cells were lysed and luciferase activity was determined. (B) Naive Huh7-Lunet cells or
cells transduced with a retroviral vector encoding a CypA- or CypB-specific shRNA or transduced with the retroviral vector control (sh-control) were
transfected with a HCV luciferase reporter replicon (sgNS3/JFH1-Luc). Four hours post transfection various concentrations of CsA or DEBIO-025 were
added, cells were incubated for 72 h and lysed. Luciferase activities were determined and normalized to the values obtained with mock-treated cells,
which was set to 100%. The background of the assay is indicated with the grey horizontal line. (C) Huh7-Lunet cells with a stable knock-down of CypA
and transduced with the empty vector (control-rescue) or the shRNA-resistant CypA wt or CypA H126Q encoding vector were transfected with
sgNS3/JFH1-Luc. Thereafter cells were treated with various concentrations of DEBIO-025 and 72 h later, cells were lysed and luciferase activity was
determined. Naive Huh7-Lunet cells were analyzed in parallel. (A–C) Means and standard deviations of a representative experiment (2 independent
repetitions) are shown.
doi:10.1371/journal.ppat.1000546.g005
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Fig. 2A) and determining replication fitness (Fig. 6C) as well as
DEBIO-025 sensitivity (Fig. 6B). In this and all subsequent
analyses we included the TEM V2440L, because it resides at the
very same position like the putative resistance mutation V2440A.
The results in Fig. 6B demonstrate that only the mutations
affecting residue 2440 in NS5A reduced DEBIO-025 sensitivity to
a significant extent. In fact, the IC50 of replicons containing the
V2440A or the V2440L substitution was increased about 5- to 10-
fold (Fig. 6B) whereas the mutations in domain 2 of NS5A had
either minor or no effect. Replication fitness of only the V2440A
mutant was reduced (about 10–15-fold as compared to the wild
type) whereas all other mutants were unaffected (Fig. 6C).
Since V2440L is a TEM, we next assessed the impact of this and
the V2440A substitution on virus production. The two mutations
were introduced into the JFH1 wild type genome and virus titers
released from cells at various time points after transfection were
determined (Fig. 6D). In agreement with our earlier report [40]
the V2440L substitution enhanced virus production without
affecting RNA replication, whereas the V2440A substitution
reduced virus production to an extent corresponding to the lower
replication. These results suggest that only V2440L is a TEM.
The data described so far show that CypA is an important
cellular determinant of HCV RNA replication and they suggest
that DEBIO-025 blocks HCV replication by interfering with
CypA. Having identified V2440L/A as DEBIO-025 resistance
conferring mutations we assumed that they might render HCV
replicons less dependent on CypA. To corroborate this assumption
we performed transient replication assays with JFH1 wild type,
JFH1 V2440L and JFH1 V2440A sgNS3-replicons in CypA knock
down cells (Fig. 7A and B, respectively). In line with our
assumption we found that replication of the V2440L mutant was
less impaired in CypA depleted cells. The analogous result was
found when we scored replication by immunofluorescence of
transfected cells (not shown). In case of the V2440A mutation, due
to reduced replication fitness only a slight but statistically
significant difference (p,0.002, a=0.05; for values 72 h and
96 h post transfection, respectively) compared to the wt replicon
was apparent (Fig. 7B). These data suggest that the mutations close
to the C-terminus of NS5A conferring DEBIO-025 resistance
render HCV replication less dependent on CypA.
Correlation between cleavage kinetic at the NS5A-B site
and CypA dependence
We have recently shown that the V2440L substitution leads to
delayed cleavage at the NS5A-B site [40]. Having identified another
substitution at the same site that also confers DEBIO-025 resistance
and lower dependence on CypA (V2440A), we wondered whether
Figure 6. Identification and characterization of mutations
conferring resistance against the antiviral activity of DEBIO-
025. (A) Design of the selectable JFH1 replicon that was used for the
selection of DEBIO-025 resistance. The construct contains the gene
encoding the neomycin phosphotransferase (neo) under control of the
HCV IRES whereas the replicase gene encoding the NS3 to NS5B
polyprotein fragment is translated under control of the EMCV IRES (E–I).
The sequence encoding the red fluorescent protein (RFP; shown as
black bar in NS5A) was inserted in frame into domain 3 of NS5A to
facilitate detection of HCV during the selection procedure. Mutations
identified in replicons that were isolated after 18 passages of cells in
double selection medium (G418 and DEBIO-025) are given above the
respective position in the polyprotein. Numbers refer to the polyprotein
sequence of JFH1. Lines in the bottom refer to the amplicons used for
nucleotide sequence analyses. Note that mutations depicted in the top
all resided in the 39 amplicon. (B) Dose-response assay of all mutations
identified in double selected replicons using the transient sgNS3/JFH1-
Luc replicon assay. Included is the V2440L mutation recently shown to
enhance virus titers without affecting RNA replication [40]. Means and
standard deviations of three independent experiments are shown. (C)
Replication competence (fitness) of sgNS3/JFH1-Luc replicons (shown
at the top of Fig. 2A) carrying one of the mutations specified in the right
in comparison to the wild type replicon (wt). Huh7-Lunet cells were
transfected with a given replicon and RNA replication was determined
by luciferase assay at given time points after transfection. Owing to the
limitation of JFH1 replication by the host cell at later time points post
transfection, only the early time points are shown. (D) Release of
infectivity from Huh7-Lunet cells transfected with the JFH1 wild type
genome (wt) or JFH1 containing the V2440L or the V2440A mutation.
Supernatants from transfected cells were harvested at given time points
and infectivity titers were determined by TCID50 assay. The background
of the assay is indicated with the horizontal dashed line. (C, D) Means
and standard deviations of a representative experiment (3 or 2
independent repetitions, respectively) are shown.
doi:10.1371/journal.ppat.1000546.g006
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performed pulse-chase experiments using a T7-based expression
system. Huh7-Lunet cells stably expressing the T7 RNA polymerase
were transfected with NS3 to NS5B polyprotein expression constructs
corresponding to the wild type or containing the V2440L or the
V2440A mutation. Proteins were radiolabeled metabolically with
[
35S] methionine/cysteine for 90 minutes and treated with non-
r a d i o a c t i v em e d i u mf o ro n eo rt w oh o u r s .C e l l sw e r el y s e da n d
NS5A- and NS5B-containing proteins were isolated by immunopre-
cipitation with mono-specific antibodies (Fig. 8A and B, respectively;
a quantification of the autoradiogram shown in panel A is given in
panel C). We found that both mutations slowed down cleavage
kinetics at the NS5A-B site, with the V2440A mutation causing a
muchstrongerdelayofcleavagethantheleucinesubstitution(Fig.8A,
B, lanes 5–7). Best visible was the accumulation of an uncleaved
NS5AB precursor protein as well as a precursor with an apparent
molecular weight of about 175 kDa corresponding most likely to
uncleaved NS4B5AB [17]. Only small amounts of these precursors
were found in case of the wild type reflecting faster cleavage at the
NS5A-B site. These results suggest a link between processing kinetic
at this site and CypA dependence of HCV replication.
To substantiate this observation, we generated additional mutants
affecting the NS5A-B cleavage site. Selection of these mutations was
guided by a multiple alignment of amino acid residues at the P7-P1
positions of the NS5A-B cleavage site in HCV isolates deposited in
the European HCV database (euHCVdb) [41] (Fig. 9A). Interest-
ingly, amino acids at positions P7-P4 of the JFH1 isolate are rather
unique amongst all the other genotypes including genotype 2
(Fig. 9A, upper half). In case of genotype 2a the P5 and P4 residues
are serine and valine, respectively. Genotype 2b isolates have in
addition a P7 glutamic acid residue and a P3 isoleucine residue.
Based on this alignment we constructed two cleavage site mutants
corresponding to the NS5A-B site of genotype 2a and (with the
exception of the P3 isoleucine) to genotype 2b (Fig. 9A, lower half).
In addition these mutations were combined with the P3 leucine
substitution (V2440L) to determine its contribution on DEBIO-025
resistance, CypA dependence and cleavage kinetics in the context of
the 2a and 2b cleavage site. As shown in Fig. 8, cleavage between
NS5A and NS5B was enhanced with mutants 2a-5AB and 2b-5AB.
A comparison of the protein pattern obtained after immunoprecip-
itation with the NS5A-specific antibody revealed that the NS5AB
precursor was well detectable right after labeling in case of the wild
type (Fig. 8A, lane 2) and this protein remained detectable
throughout the chase period, albeit at low amounts (lane 3, 4). In
caseof the 2a and the 2b mutants the amounts of this precursor were
lower after the 1 h labeling period and it was not detectable at later
time points (lane 11–16). However, upon insertion of the V2440L
substitution into eachof these mutants, processing was again delayed
comparedtothewildtypeandcleavagekineticwassimilartotheone
observed with the V2440L single mutant (compare lanes 17–22 with
8–10 in Fig. 8A–B and quantification in Fig. 8C).
Upon transfection of Huh7-Lunet cells with replicons contain-
ing these mutations, we found that save for the 2b-5AB mutant,
which was slightly impaired, replication of all the other mutants
was well comparable to wild type (Fig. 9B). To our great surprise
mutants 2a-5AB and 2b-5AB showed an about 10-fold increased
DEBIO-025 sensitivity (Fig. 9C) and replicated less efficiently in
stable CypA knock-down cells (Fig. 9D). However, the analogous
mutants containing in addition the V2440L substitution were
again less sensitive to DEBIO-025 (Fig. 9C) and replicated more
efficiently in CypA knock-down cells (Fig. 9D). These results reveal
a correlation between cleavage kinetics at the NS5A-B site,
DEBIO-025 resistance and CypA dependence (Table 2). Delay of
cleavage kinetics correlates with low DEBIO-025 sensitivity and
reduced CypA dependence whereas ‘hyper-processing’ correlates
with increased DEBIO-025 sensitivity and CypA dependence.
Given the link between the V2440L mutation and enhanced
HCV assembly, we tested all cleavage site mutations for their effect
on virus production. As shown in Fig. 9E all cleavage site
mutations increased virus titers and kinetics. With the exception of
the 2b-5AB V2440L mutant, peak titers were reached already
24 h post transfection with all mutants and titers were elevated
100- to 1.000-fold. Especially for the 2a-5AB mutant, already 7 h
after transfection infectious virus was detected in the culture
supernatant (compare 2a-5AB also with the very efficient Jc1 in
Fig. 9E). A significant, but less pronounced enhancement of
kinetics and overall production of virus was achieved with mutant
2b-5AB. When the V2440L substitution was introduced into these
mutants, kinetics were reduced, best visible with the 7 h values
(Fig. 9E). In summary, our results reveal a correlation between
cleavage kinetics at the NS5A-B site, DEBIO-025 resistance and
CypA dependence. The data also suggest that cleavage kinetics at
the NS5A-B site and virus assembly may be linked.
Discussion
Exploitation of host cell machineries to achieve efficient replication
is a strategy shared by all viruses. In case of HCV, Cyps have gained
increasing interest because of the possibility to interfere pharmaco-
logically with their activity thus providing a new approach for
Table 1. Mutations identified in JFH1/RFP replicons after selection for DEBIO-025 resistance.
HCV protein Substitution frequency
a Amino acid substitution Amino acid appearance
b
NS3 helicase 7/7 Y 1421 F (391) Y, F
NS5A domain II 5/7 D 2229 G (253) D, E, A
NS5A domain II 7/7 L 2266 F (290) E, L, R, H, M, D, N, G
NS5A domain III 7/7 V 2440 A (464) V, A, I
NS5A domain III
c n.a. V 2440 L (464) V, A, I
aNumber of DNA clones in which the mutation was found vs. number of clones that were analyzed. Note that all mutations were found with the 39 PCR fragment
(Fig. 6A) and therefore the identified mutations coexisted in the same replicon RNA.
bAmino acids found at the corresponding position of the polyprotein of HCV isolates available in the European HCV database and belonging to genotypes 1a,b,c;
2a,b,c,i,k; 3a,b,k; 4a,d,f; 5a; 6a,b,c,e,f,g,h,i,j, k,l,m,n,p; 7a.
cVirus titer enhancing mutation; data taken from [40].
n.a., not applicable.
Bracketed numbers refer to positions of the individual HCV protein of the JFH1 isolate.
doi:10.1371/journal.ppat.1000546.t001
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CypA but not CypB is the major player for HCV replication. This
conclusion is supported by the profound impairment of replication by
s t a b l eC y p A ,b u tn o tC y p Bk n o c k - d o w na n dt h er e s c u eo fv i r a l
replication by expression of CypA in these cells. Rescue was not
achieved by expression of the active site mutant H126Q. This
mutation resides in the hydrophobic pocket of CypA and causes a
reduction of PPIase activity to about 1% of the wild type [36,37].
Although this result argues for a role of PPIase activity in HCV
replication, it should be kept in mind that CypA mutants that are
impaired in isomerase activity have reduced substrate binding
[37,43]. Thus, PPIase activity and substrate binding cannot be
separated genetically and therefore, the exact role of isomerase
activity in HCV replication remains to be determined.
Cyps are a diverse group of proteins that share a PPIase activity
and a 109 amino acids long Cyp-like domain [23]. There are 7
major Cyps in humans that differ in their N- and C-terminal
sequences, which determine the intracellular localization of a given
Cyp. For instance, CypA (as well as Cyp40 and CypNK) are
cytosolic whereas CypB and CypC possess N-terminal signal
sequences, which target the proteins to the ER-resident secretory
machinery. CypD has a signal sequence recruiting the protein to
mitochondria and CypE is localized in the nucleus. Although the
role of Cyps in HCV replication has been established in several
reports, conflicting results exist as to which individual Cyp is
required. Two studies identified CypB, but not CypA, as the key
player in HCV replication [24,25]. One study describes that
CypA, B and C are required [44] and the study by Yang and co-
workers suggests that CypA, but not CypB and C is critical for
HCV replication [26]. The results presented in this report are in
full support of the work by Yang and colleagues. We also identify
CypA as the key player in HCV replication and show that this host
Figure 7. A mutation close to the NS5A/B cleavage site confers resistance to DEBIO-025 and renders HCV replication less
dependent on CypA. (A) Replication of sgNS3/JFH1-Luc wt and the V2440L replicon in Huh7-Lunet cells with a stable knock-down of CypA or
transduced with the retroviral vector control (sh-control). Cells were lysed at given time points after transfection with each of the replicon RNAs and
luciferase activity in cell lysates was determined. Values were normalized to the 4 h value to exclude differences due to transfection efficiency. Note
the higher replication of the V2440L mutant as compared with the wild type in CypA knock-down cells. (B) Experimental setup as in A, with the
difference that the V2440A- and not the V2440L-mutant was used. Means and standard deviations of two independent experiments are shown in
each panel.
doi:10.1371/journal.ppat.1000546.g007
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reasons for the discrepant results is not known, but may in part be
due to the use of different cell systems, HCV isolates or
experimental conditions such as utilized siRNAs. However, we
note that in our study HCV replication was impaired upon CypA
knock-down both in Huh7-Lunet and Huh7.5 cells; two widely
used Huh7-derived cell clones that are highly permissive for HCV
replication. We also note that the impairment of HCV replication
was found both with the JFH1 and the Con1 isolate similar to
what Yang and colleagues described [26]. In support of these
findings, a very recent study also describes CypA as the main actor
in HCV replication [45]. Considering the subcellular localization,
the cytosolic CypA is more likely to interact with the HCV
replicase that also resides on the cytosolic side of the ER
membrane, in contrast to the ER luminal CypB. In addition,
CypB and C are expressed 10–150-fold lower in hepatoma cells as
Figure 8. Alteration of the kinetics of polyprotein processing at the NS5A-B cleavage site by mutations conferring DEBIO-025
resistance. (A, B) Huh7-Lunet/T7 cells were transfected with subgenomic NS3 to NS5B JFH1 expression constructs derived from the wild type or
mutants specified at the top of each panel or with the empty vector (pTM1-2; lane 1). After 24 h cells were pulse-labeled for 90 min with [
35S]
methionine/cysteine. Cells were lysed immediately (0) or incubated with non-radioactive medium for 1 or 2 additional hours. Immunoprecipitation
was performed using either an NS5A- (A) or NS5B-specific antibody (B). Molecular weights are given on the left, arrows to the right point to the
respective HCV proteins detected. (C) Amounts of unprocessed NS5AB and NS4B5AB precursors were quantified by phosphoimaging. Values
obtained with the phosphoimage displayed in the upper panel are shown in panel C. Similar ratios were obtained with the phosphoimage of the
NS5B-specific immunoprecipitation (data not shown).
doi:10.1371/journal.ppat.1000546.g008
Role of Cyclophilin A for HCV Replication
PLoS Pathogens | www.plospathogens.org 12 August 2009 | Volume 5 | Issue 8 | e1000546compared to CyPA thus increasing the likelihood of the latter to
interact with the viral replicase [26].
In an attempt to study the mode-of-action of CypA, we wanted to
exploit the possibility to interfere with this protein pharmacologi-
cally by using DEBIO-025, a compound that shows promise in
clinical trials for the treatment of chronic hepatitis C [42]. The
advantage of this compound is its higher anti-HCV activity as
compared to CsA and reduced immunosuppressive activity, the
latter being due to reduced calcineurin affinity [5,46]. As shown
here, dose-response assays with cell lines expressing various levels of
CypA confirm that DEBIO-025 indeed targets this host cell factor:
HCV replication can be sensitized to the antiviral activity of
DEBIO-025 by stable knock-down of CypA whereas over-
expression of CypA leads to partial DEBIO-025 resistance.
Although these results confirm CypA as a DEBIO-025 target, it is
not known whether other Cyps are also affected by this compound,
because interference with these proteins (e.g. CypB) has no effect on
HCV replication, which was used as a read-out in our assays.
By using replicons to select for DEBIO-025 resistance we
identified Y1421F (Y391F in NS3) that resides in the NS3 helicase
domain, two mutations in domain 2 of NS5A (D2229G/D253G;
L2266F/L290F) and one mutation at the P3 cleavage site position
of the NS5A-B junction (V2440A/V464A). Among these muta-
tions, only V2440A (V464A in NS5A) reduced DEBIO-025
sensitivity and rendered HCV replication less dependent on CypA.
We had recently identified a mutation at the very same site that
enhances virus assembly about 100-fold without affecting RNA
replication (V2440L/V464L) [40]. As shown here this mutation
also confers DEBIO-025 resistance, renders HCV replication less
dependent on CypA and slows down processing at the NS5A-B
site. Results obtained with additional mutations at the NS5A-B site
revealed a correlation between processing kinetics and CypA
dependence (Table 2): mutants with slower cleavage kinetic
require lower level of CypA and are less sensitive to DEBIO-025
treatment compared to wild type whereas mutants with acceler-
ated cleavage kinetic are more dependent on CypA and more
Figure 9. Properties of NS5A-B cleavage site mutants. (A) Alignment of amino acid consensus (con) sequences of various HCV genotypes or
individual HCV isolates (H77, Con1, JFH1) at the P-side of the NS5A-B cleavage site. JFH1 (upper lane) was used as master sequence. Numbers at the
top refer to the P-side positions. Amino acid sequences of cleavage site mutants are given in the lower part of this panel (CONSTRUCTS). (B) Time
course of replication of subgenomic sgNS3/JFH1-Luc replicons specified in the top. Only the early time points up to 24 h post infection are shown. (C)
Dose-response assay of cleavage site mutants. Subgenomic replicons were transfected into Huh7-Lunet cells and treated 4 h later with escalating
concentrations of DEBIO-025. After 72 h cells were lysed and luciferase activity was determined. Values are normalized to transfected control cells
that were mock treated. The means and standard deviations of two independent experiments are shown in panel B and C. (D) Replication kinetic of
cleavage site mutants in Huh7-Lunet cells with a stable knock-down of CypA. Cells transfected with constructs specified in the top were lysed at
given time points and luciferase activity was determined. Values were normalized for transfection efficiency as determined with the 4 h value. (E)
Impact of NS5A-B cleavage site mutants on release of infectivity. Genomes depicted at the bottom of the panel were transfected into Huh7-Lunet
cells and release of infectious HCV particles into the supernatant was determined by TCID50 assay at time points specified in the top. (D–E) The
background of the assay is indicated with the horizontal dashed line. Means and standard deviations of a representative experiment are shown.
doi:10.1371/journal.ppat.1000546.g009
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about the underlying mechanism, but for any model the following
observations should be considered:
1. CypA and CypB are PPIases which appear to bind to the C-
terminal region of NS5B [24,26];
2. CypA and/or CypB may induce a conformational change in
NS5B by acting on a critical proline residue in the C-terminal
region of NS5B [24];
3. Based on the X-ray crystal structure of NS5B, the Cyp binding
site appears to be poorly accessible for protein-protein
interaction in the folded NS5B molecule and may only be
accessible in the unfolded protein, e.g. during protein synthesis
(reviewed in [47]);
4. Cleavage at the NS5A-B site occurs rapidly and NS5A-B
precursors are present in very low amounts [17,18].
One possible explanation for our observations is that the CypA
binding site in the C-terminal region of NS5B might be accessible
only in an extended (non-folded) conformation right after protein
synthesis. Proper folding of NS5B may require liberation of the N-
terminus from the polyprotein (i.e. cleavage at the NS5A-B site).
NS5B folded in the absence of CypA may adopt a conformation
that is enzymatically inactive or that is not competent to be
incorporated into the replicase complex [48]. In this model
binding of CypA to NS5B would be required to induce a
conformation necessary for replicase formation or activity. Binding
however, would be possible only during a short time period, i.e.
prior to or shortly after release of full length NS5B from the
polyprotein. In case of a delayed processing (V2440L/A) the time
during which the CypA binding site is accessible is extended and
therefore lower amounts of CypA would suffice to bind to NS5B.
Nevertheless, also under these circumstances CypA is required for
HCV replication thus explaining why these replicons are still
susceptible to DEBIO-025, albeit to a lesser extent. In case of
hyper-processing the time for CypA binding would be much
shorter and therefore the chance for interaction with NS5B would
be lower. This can however be compensated by higher CypA
amounts. This model would also explain why the mutations
modulating NS5A-B processing do not have an effect on RNA
replication in naı ¨ve cells. Under normal conditions, CypA levels
are not limiting and even in case of the hyper-processing mutants
CypA amounts are sufficient to bind to NS5B. Only when CypA
levels are reduced either by knock-down of CypA expression or by
DEBIO-025 treatment the chance that CypA can bind to NS5B
during the much shorter time period, compared to wild type,
becomes apparent. In contrast, delaying processing will extend the
time for CypA binding and therefore even lower CypA amounts
would be sufficient for binding to NS5B. However, a too slow
processing at the NS5A-B site appears to impair replicase activity
as deduced from the reduced replication of the V2440A mutant.
The CsA resistance mutations residing in domain 2 of NS5A
that have been described in a recent study [27] may affect NS5B
activity indirectly by altering binding of NS5A to NS5B. It has
been shown that NS5A binds to NS5B and this interaction appears
to modulate RdRp activity [49]. Alternatively, these mutations
may affect directly a function of NS5A required for RNA
replication [50] or polyprotein cleavage kinetics, but these
possibilities need to be addressed. Finally, the impact of altered
cleavage kinetics on HCV assembly might be an epiphenomenon
caused by the mutations in domain 3 of NS5A itself that is a major
determinant of virus assembly [15,16].
Another surprising observation we made is the higher sensitivity
of replication of JFH1 full length genomes towards CypA
depletion and the impairment of virus production. This observa-
tion suggests that CypA may have an additional target outside of
the minimal replicase. The most likely candidate is NS2, because it
contributes indirectly to RNA replication and is required for
assembly [12,13] whereas all other proteins residing in the N-
terminal domain of the polyprotein (core, E1, E2, p7) are
completely dispensable for RNA replication. In fact, the stronger
inhibition observed with the JFH1 sgNS2-replicon containing NS2
and the impairment of HCV assembly supports this assumption.
Since NS2 contributes to RNA replication indirectly by cleaving
off itself from NS3, a possible explanation is that CypA supports
proper folding of NS2. However, in addition to a viral factor CypA
may also be required for host cell factor(s) contributing to virus
production. In fact, preliminary results suggest that CypA may be
required for integrity of lipid droplets (A. Kaul, C. Berger, and R.
Bartenschlager, unpublished observation), which play a key role in
HCV assembly [20–22]. Further studies will be required to
identify CypA-dependent viral and host cell factors required for
HCV RNA replication, assembly and eventually egress.
Materials and Methods
Cell culture and cell lines
All cell lines were grown in Dulbecco’s modified minimal
essential medium (DMEM; Life Technologies, Germany) supple-
mented with 2 mM L-glutamine, nonessential amino acids, 100 U/
Table 2. Summary of phenotypes of NS5A mutants.
Mutant Kinetic
1 DEBIO-025 resistance CypA dependence Replication Assembly
2
V2440A QQ q Q Q n.d.
V2440L Qq Q u.a. q
2a-5AB qQ q u.a. q
2b-5AB qQ q u.a. q
2a-5AB V2440L Qq Q u.a. q
2b-5AB V2440L Qq Q u.a. q
1Kinetic of cleavage at the NS5A-B site.
2Production of infectious virus as deduced from TCID50 assay.
Q, lower than wild type.
q, higher than wild type.
n.d., not determined.
u.a., unaffected.
doi:10.1371/journal.ppat.1000546.t002
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serum. The experiments wereperformed either in Huh7-Lunet cells
supporting high level RNA replication or Huh7.5 cells that are
highly infectable [51,52]. For selection of DEBIO-025 resistant
JFH1 replicons Huh7-Lunet sgNS3/JFH1-neo/RFP replicon cells
[39] were double-selected for 18 cell passages with 500 mg/ml of
G418 and 0 or 0.5 or 1 mg/ml of DEBIO-025. For transient dose
response experiments subgenomic Luc-JFH1 replicons were
transfected into Huh7-Lunet cells and 4 h post electroporation
cells were treated with various concentrations of Cyclosporine A
(CsA) or DEBIO-025, respectively. Seventy two hours later the
impact on replication was determined by luciferase assay.
Plasmid construction
All nucleotide and amino acid numbers refer to the JFH1
genome (GenBank accession no. AB047639) or the Con1 genome
(GenBank accession number AJ238799). The chimera Jc1-Luc was
described recently [33]. For replication analyses the subgenomic
reporter replicon pFKI389Luc/NS3-39_dg_JFH (abbreviated as
sgNS3/JFH1-Luc) and the replication deficient mutant carrying a
deletion of the NS5B active site (sg/luc/JFH1/DGDD) were used
[39]. The basic Con1 construct pFK-rep PI-luc/ET has been
described somewhere else [31]. To generate the subgenomic JFH1
replicon construct pFKI389Luc/NS2-39_dg_(designated sgNS2/
JFH1-Luc in this report) we performed two separate PCRs: the
first one with sense primer S/EMCV190 (59-AATGCAAGGT
CTGTTGAATGT-39) and antisense primer A/EMCV-NS2 (59-
CGTGCACAGGTGCGTCATACATGGTATCATCGTGTTT
TTCA-39) and pFKI389Luc/NS3-39_dg_[39] as template; the
second one with primers A/JFH1/2894 (59-TGACGGCC-
CACGCGATGCCAT-39) and S/EMCV-NS2 (59-TGAAAA
ACACGATGATACCATGTATGACGCACCTGTGCACG-39)
and pFKI389Luc/Core-39_dg_JFH [32] as template. Fragments
were combined by overlap-PCR using S/EMCV190 and A/
JFH1/2894 and the resulting DNA fragment was inserted into
pFKI389Luc/Core-39/DelE1E2_dg_JFH [32]. The final construct
pFKI389Luc/NS2-39_dg_JFH contains (59 to 39) the T7 promoter
sequence fused to nucleotides 1 to 389 of the JFH1 consensus
sequence, the firefly luciferase gene, the encephalomyocarditis
virus (EMCV) IRES, the NS2 to 5B coding sequence, the 39 NTR
of JFH1, the hepatitis delta virus genomic ribozyme (dg) and the
T7 terminator sequence. Amino acid substitutions were intro-
duced by PCR-based site-directed mutagenesis and amplified
DNA fragments were analyzed by automated nucleotide sequenc-
ing using an ABI 310 sequencer (Applied Biosystems, Darmstadt,
Germany).
Generation of stable knock-down and rescue cell lines
For CypA and CypB knock-down microRNA-based shRNA
lentiviral vectors were produced by co-transfecting 293T cells with
transfer vectors encoding the puromycin resistance gene and a
shRNA targeting CypA, CypB, or a control shRNA targeting
luciferase, the HIV-1 packaging plasmid psPAX2, and a VSVg
expression plasmid (pMD2.G) using Lipofectamine 2000 (Invitro-
gen). The shRNA targeting sequences were: luciferase, 59-
tacaaacgctctcatcgacaag-39 (not present in the luciferase gene of
the reporter replicon and reporter virus), CypA, 59-ctggattgca-
gagttaagttta-39; and CypB, 59-gccgggtgatctttggtctctt-39. Transfec-
tion medium was changed the next day and viral supernatant was
harvested 48 hrs after transfection, clarified by centrifugation
(5 min at 2006g), and filtered through a 0.45 mm syringe filter
(Sarstedt). Huh7-Lunet and Huh7.5 cells were transduced on two
consecutive days and placed into selection medium containing
5 mg/ml puromycin (Sigma) 72 h after transduction. For selected
Huh7-Lunet cell pools, knock-down of CypA and CypB was stable
for at least 20 passages and cell growth as well as viability was not
affected (long-term passage of Huh7.5 cell pools was not
performed). For stable over-expression of CypA in CypA knock-
down cells we used a lentiviral vector system. 293T cells (5610
5)
were seeded in each well of a 6-well cell culture plate in complete
DMEM. About 24 h later, cells were transfected with lentiviral
plasmids by using Lipofectamine 2000 or Lipofectamine LTX/
Plus Reagent (Life Technologies) according to the instructions of
the manufacturer. To generate the CypA rescue cell lines, 2.5 mg
of the transfer vector pWPI-CypAwt or pWPI-CypA/H126Q, was
transfected together with 2 mg of the packaging vector (pCMV)
and 0.6 mg of the VSV envelope vector (pMD.G) into 293T cells
by lipofection as described above. After 16–24 h medium (2 ml)
was replaced by fresh one and an additional 24 h later culture
supernatant was filtered through 0.45 mM pore size polyvinylidene
difluoride (PVDF) syringe filter (Carl Roth GmbH, Karlsruhe
Germany) and used for transduction. Huh7-Lunet/CypA knock-
down cells were seeded at a density of 1–2610
4 cells per well of a
12-well plate and inoculated with 0.5–1 ml of filtered supernatant.
Twenty four hours later, inoculation was repeated. Two to three
days after transduction medium was replaced by fresh cell culture
medium containing puromycin and/or blasticidin S. Drug
concentrations were increased steadily during cell passages up to
10 mg/ml puromycin in case of Huh7-Lunet or 20 mg/ml in case
of Huh7.5 and 20 mg/ml blasticidin S (Life Technologies).
In vitro transcription and electroporation of HCV RNAs
In vitro transcription and electroporation of HCV RNAs was
performed as described previously [40]. Transfected cells were
immediately diluted into complete DMEM and seeded as required
for the given assay.
Preparation of total RNA, amplification of replicon RNA
by RT-PCR and cloning of amplified DNA fragments
Total RNA was isolated from a confluent 6 cm diameter dish of
Huh7-Lunet cells containing the sgJFH1-neo/RFP replicon by
using the Nucleo Spin RNAII Kit (Macherey-Nagel, Du ¨ren,
Germany) as recommended by the manufacturer. One mg total
RNA and 50 pmol of primer A9482 (59-GGA ACA GTT AGC
TAT GGA GTG TAC C-39) were used for cDNA synthesis by
using the Expand-RT system (Roche, Mannheim, Germany) as
recommended by the manufacturer. Two to four microliters of the
reaction mixture were used to amplify the complete open reading
frame in two overlapping fragments with the Expand Long
Template PCR kit (Roche) according to the instructions of the
manufacturer. To amplify the 59 half of the replicon, PCR was
performed with primers S59-EcoRI (59-TGT CTT CAC GCA
GAA AGC GCC TAG-39) and A4614 (59-CTG AGC TGG TAT
TAT GGA GAC GTC C-39) and the PCR product was inserted
into sgJFH1-Luc after restriction with EcoRI and SpeI. The 39
half of the HCV genome was amplified with primers S3813 (59-
GGA CAA GCG GGG AGC ATT GCT CTC-39) and A9466-
MluI (59-AGC TAT GGA GTG TAC CTA GTG TGT GCC-39)
and after restriction with SpeI and MluI, the fragment was
inserted into pFK-I389neo/NS3-39/Con [35]. Sequence analysis
was performed with a set of primers covering the complete
replicon sequence.
Indirect immunofluorescence
Huh7-Lunet and Huh7.5 derived cell lines were seeded onto
glass cover slips in 24-well plates at a density of 2–4610
4 cells per
well. Three days after seeding cells were fixed by treatment with
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incubated for 30 min in 5% normal goat serum or bovine serum
albumin (diluted in PBS) and incubated for 1 h at room
temperature (RT) with one of the following primary antibodies:
antiCyPA rabbit polyclonal antiserum (BIOMOL International,
LP) diluted 1:400, or antiCypB rabbit polyclonal antiserum
(Affinity Bio Reagents) diluted 1:800, or antiNS5A mouse
monoclonal antibody (9E10) [53]. After an extensive wash with
PBS, cells were treated with Alexa Fluor 488 or 546 conjugated
antibodies, targeting rabbit or mouse IgG domains (dilution
1:1,000 in normal goat serum) for 1 h at RT in complete darkness.
Unbound secondary antibodies were removed by washing three
times with PBS and once with water. DNA was stained with 49,6 9-
diamidino-2-phenylindole (DAPI; Molecular Probes, Karlsruhe,
Germany) for 1 min at RT. Finally samples were mounted on
slides with FluormountG (Southern Biotechnology Associates,
Birmingham, USA) and analyzed by using fluorescence micros-
copy. For quantitation of immunofluorescence signals raw pictures
were imported into the image J software package and pixel
intensities based on 8-bit gray value were determined using the
histogram function of the program (National Institutes of Health,
Bethesda, MD, USA).
Luciferase assays
Quantification of luciferase reporter activity was used to
determine transient HCV RNA replication as described previously
[33]. In brief, transfected Huh7-Lunet cells were resuspended in
41 ml complete DMEM and 1.5 ml of the suspension was seeded
in each well of a 12-well plate. For each time point, duplicates of
wells were harvested. For dose response experiments, 4 h post
electroporation transfected cells were treated in duplicate with
different concentrations of cyclosporine A (CsA) or DEBIO-025
and analyzed 72 h later by luciferase assay. Cells were washed
once with PBS, 350 ml of lysis buffer (0.1% Triton X-100, 25 mM
glycylglycine, 15 mM MgSO4, 4 mM EGTA and 1 mM DTT,
pH 7.8) was added and freeze-thaw lysates were prepared. For
each well, two times 100 ml lysate was mixed with 360 ml assay
buffer (25 mM glycylglycine, 15 mM MgSO4, 4 mM EGTA,
1 mM DTT, 2 mM ATP and 15 mM K2PO4, pH 7.8) and, after
addition of 200 ml of a luciferin solution (200 mM luciferin,
25 mM glycylglycine, pH 8.0), measured for 20 s in a luminom-
eter (Lumat LB9507; Berthold, Freiburg, Germany). Kinetic of
replication was determined by normalizing the relative light units
(RLU) of the different time points to the respective 4 h value. For
dose response experiments the RLU obtained with cyclosporine A
(CsA) or DEBIO-025 treated cells were normalized to the
corresponding values obtained with untreated cells.
Metabolic radiolabeling of proteins and
immunoprecipitation
A total of 2.5610
5 Huh7-Lunet/T7 cells [54] were seeded in
each well of a 6-well cell culture plate in complete DMEM. About
24 h later, cells were transfected with 2.5 mg per well pTMNS3-
39JFH1 wild type or analogous constructs containing mutations
specified in the results section or empty vector (pTM1-2) [55].
Transfection was performed by using Lipofectamine LTX/Plus
Reagent (Life Technologies) according to the instructions of the
manufacturer. After 4 h, cells were washed once with methionine/
cysteine-free medium and starved for 1 h. For radiolabeling cells
were incubated for 90 min in 1 ml methionine/cysteine-free
medium, supplemented with 2 mM glutamine, 10 mM Hepes
(pH 7.5), and 150 mCi/ml of Express Protein labeling mix (Perkin
Elmer, Boston). Cells were lysed either directly or washed with
PBS and incubated in complete DMEM for 1 or 2 h. Cell lysates
were prepared by using NPB (50 mM Tris-Cl [pH 7.5], 150 mM
NaCl, 1% Nonidet P-40, 1% sodium deoxycholate, 0.1% SDS, 1/
10,000 vol aprotinin (1 U/ml), 1/1,000 vol leupeptin (4 mg/ml)
and 1/100 vol phenyl-methyl-sulfonyl-fluoride (100 mM)) and
cleared by centrifugation at 13,000 g for 15 min at 4uC. Cleared
lysates were used for immunoprecipitation using either the NS5A-
specific monoclonal antibody 9E10 [53] or a polyclonal NS5B-
specific antibody. Immunocomplexes were dissolved in 70 ml2 6
sample buffer (400 mM Tris pH 8.8, 10 mM EDTA, 0.2%
bromophenolblue, 20% sucrose, 3% SDS and 2% ß-mercapto-
ethanol), separated in a 10% polyacrylamide-SDS gel and
analyzed by autoradiography. HCV-specific bands were quanti-
fied by phosphoimaging using the QuantityOne software (BioRad,
Munich, Germany).
Western blot analysis
Huh7-Lunet cells of a confluent 6-well cell culture plate were
washed once with ice-cold PBS and lysed with NP40 buffer buffer
(50 mM Tris-HCl pH 8, 150 mM NaCl, 1% NP40). After 30 min
incubation at 4uC, cell debris was pelleted by centrifugation for
30 min at 10.000 g and at 4uC. Four mg of cleared supernatant
was diluted in 26sample buffer, heated 5 min at 95uC and loaded
onto a 12.5% polyacrylamide-SDS gel. After electrophoresis
proteins were transferred to a PVDF membrane (PerkinElmer
Life Sciences) for 1 h with an electric current of 1 mA/cm
2.
Membrane was blocked in PBS supplemented with 0.5% Tween
(PBS-T) and 5% dried milk (PBS-TM) for at least 1 h prior to 1 h
incubation with primary antibody diluted 1:1,000 in PBS-TM.
Membrane was washed 3 times with PBS-T and incubated for 1 h
with horseradish-peroxidase conjugated anti rabbit secondary
antibody diluted 1:10,000 in PBS-TM. Bound antibodies were
detected after 3 times washing with the ECL Plus Western Blotting
Detection System (GE Healthcare Europe, Freiburg, Germany).
Quantitation of HCV core protein
HCV core protein in transfected cells or cell culture
supernatants was quantified using the OrthoH trak-C
TM ELISA
kit (Ortho Clinical Diagnostics, Neckargemu ¨nd, Germany).
Lysates of transfected Huh7-Lunet cells were prepared by addition
of 1 ml per 6 cm diameter culture dish of PBS containing 1%
Triton X-100, 1/10,000 vol aprotinin (1 U/ml), 1/1,000 vol
leupeptin (4 mg/ml) and 1/100 vol phenyl-methyl-sulfonyl-
fluoride (100 mM). Lysates were cleared by centrifugation
(18,0006g; 5 min) and samples were diluted 1:10 or higher and
processed for ELISA according to the manufacturer’s protocol.
Culture supernatants were filtered through 0.45 mm pore-size
filters and used directly for core ELISA. Colorimetric measure-
ments were performed using a Sunrise colorimeter (Tecan Trading
AG, Switzerland). Kinetic of replication was determined by
normalizing the intracellular core amount of the different time
points to the respective 4 h value. To determine the efficiency of
core protein release, the percentage of extracellular core to total
core protein (the sum of intra- and extracellular core protein) was
calculated.
Determination of virus titers in cell culture supernatants
Virus titers were determined as described elsewhere with slight
modifications [52]. Huh7.5 target cells were seeded at a
concentration of 1.1610
4 cells per well of a 96-well plate in a
total volume of 200 ml complete DMEM. Twenty four hours later,
serial dilutions of virus containing supernatant were added with 6
wells per dilution. Three days later, cells were washed with PBS
and fixed for 20 min with ice-cold methanol at -20uC. After three
washes with PBS NS5A was detected with a 1:2,000 dilution of
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NS3 was detected with a 1:100 dilution of antibody 2E3 (kindly
provided by H. Tang, Florida State University, USA) in PBS for
1 h at RT. Cells were washed again three times with PBS and
bound primary antibodies were detected by incubation with
peroxidase – conjugated or Alexa Fluor 546 – conjugated anti
mouse antibody (Sigma – Aldrich), respectively, diluted 1:1,000 in
PBS. After 1 h incubation at room temperature cells were washed
three times with PBS and in case of peroxidase – conjugated
antibody the Vector NovaRED substrate kit (Linaris Biologische
Produkte GmbH, Wertheim, Germany) was used for detection.
Virus titres (50% tissue culture infective dose per ml (TCID50/ml))
were calculated based on the method of Spearman and Ka ¨rber
[56,57].
Supporting Information
Figure S1 Impact of stable CypA or CypB knock-down on
Dengue virus RNA replication. Huh7-Lunet cells (left panel) and
Huh7.5 cells (right panel) either stably transduced with the shRNA
vector (sh-control) or a vector encoding the CypA- or CypB-
specific shRNA or naive cells were transfected with a subgenomic
luciferase reporter replicon derived from the Dengue virus 2
isolate NGC (shown at the top). Cells were lysed at given time
points after transfection, and luciferase activity in cell lysates was
determined. Means and standard deviations of a representative
experiment are shown. Details of this replicon will be described
elsewhere. Cap, RNA cap structure; luc, firefly luciferase; ubi,
ubiquitin.
Found at: doi:10.1371/journal.ppat.1000546.s001 (0.34 MB TIF)
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